Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Equities researchers at Jefferies Financial Group raised their Q4 2019 EPS estimates for shares of Eiger Biopharmaceuticals in a note issued to investors on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biotechnology company will earn $1.45 per share for the quarter, up from their prior forecast of $1.41. Jefferies Financial Group also issued estimates for Eiger Biopharmaceuticals’ FY2021 earnings at $0.10 EPS and FY2023 earnings at $3.10 EPS.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. Wedbush set a $43.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th. ValuEngine downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Finally, BidaskClub downgraded Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 14th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Eiger Biopharmaceuticals has a consensus rating of “Buy” and a consensus target price of $31.29.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $0.05.
Several large investors have recently added to or reduced their stakes in EIGR. Jane Street Group LLC bought a new stake in shares of Eiger Biopharmaceuticals in the fourth quarter valued at about $114,000. Jefferies Group LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the first quarter worth about $164,000. Wedbush Securities Inc. purchased a new stake in shares of Eiger Biopharmaceuticals during the first quarter worth about $179,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eiger Biopharmaceuticals during the third quarter worth about $194,000. Finally, Millennium Management LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth about $255,000. Institutional investors and hedge funds own 78.50% of the company’s stock.
In other Eiger Biopharmaceuticals news, Director Thomas John Dietz bought 5,000 shares of the firm’s stock in a transaction dated Monday, April 22nd. The stock was acquired at an average cost of $11.05 per share, for a total transaction of $55,250.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at $165,750. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders have bought 7,250 shares of company stock valued at $80,130. Corporate insiders own 5.80% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.